GlassScriptPhysician profile
Jay K Ghadiali
NPI 1053760835
$9,585.82
in general payments reported to CMS, 2019-2025
41 companies · $2,630 in 2025
The $2,630 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $108 · 2021: $398 · 2022: $1,490 · 2023: $2,293 · 2024: $2,667 · 2025: $2,630.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,645 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $400 · Gift: $350 · Education: $194.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,645.33 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $400.00 |
| Gift | $350.00 |
| Education | $194.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,788.36 | 2021-2025 | |
| Amgen INC. | $1,056.66 | 2021-2025 | Enbrel, Tavneos, Otezla |
| Astrazeneca Pharmaceuticals LP | $826.42 | 2021-2025 | Saphnelo |
| Janssen Biotech, INC. | $665.22 | 2021-2024 | Tremfya, Simponi Aria, Simponi |
| Ucb, INC. | $483.05 | 2022-2025 | Cimzia, Bimzelx |
| Novartis Pharmaceuticals Corporation | $437.19 | 2021-2025 | |
| Genentech USA, INC. | $389.20 | 2021-2025 | Actemra, Rituxan |
| Pfizer INC. | $360.93 | 2022-2025 | |
| Ani Pharmaceuticals, INC. | $351.30 | 2022-2025 | Purified Cortrophin Gel |
| Celltrion, INC. | $350.00 | 2025 | Stoboclo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $254.94 | 2021-2024 | Cyltezo, Spevigo |
| Organon LLC | $253.23 | 2021-2025 | Hadlima, Renflexis |
| Fresenius Kabi USA, LLC | $242.22 | 2023-2025 | Idacio, Tyenne |
| Lilly USA, LLC | $224.46 | 2021-2025 | Taltz |
| E.R. Squibb & Sons, L.L.C. | $205.30 | 2021-2025 | Orencia |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Ghadiali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.